Skip to main content
Celgene acquires rights to BeiGene's PD-1 inhibitor
7/11/2017

Celgene acquired exclusive rights of BeiGene's PD-1 inhibitor BGB-A317, developed for non-hematological indications, and its commercial operations in China. BeiGene will receive $263 million in licensing fees and up to $980 million in milestones and royalties.

Full Story: